Screener
West Pharmaceutical Services WST Property, plant, and equipment additions
Property, plant, and equipment additions at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by West Pharmaceutical Services in its filing.
Tagged under the XBRL concept us-gaap:SegmentExpenditureAdditionToLongLivedAssets.
The source filing: West Pharmaceutical Services’s 10-Q, filed July 23, 2026.
- Filed
- Jul 23, 2026, 4:15 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000105770-26-000099
| ($ in millions) / Capital Expenditures | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Proprietary Products | $35.4 | $48.5 | $71.9 | $100.4 |
| West Vantage | 5.1 | 25.5 | 10.7 | 43.6 |
| Corporate and Unallocated | 2.7 | 1.2 | 3.3 | 2.5 |
| Total consolidated | $43.2 | $75.2 | $85.9 | $146.5 |
Item 1. FINANCIAL STATEMENTS (UNAUDITED)
FAQ
- What is West Pharmaceutical Services's property, plant, and equipment additions?
- West Pharmaceutical Services (WST) reported property, plant, and equipment additions of $43.2M in Q2 2026.
- How has West Pharmaceutical Services's property, plant, and equipment additions changed year-over-year?
- West Pharmaceutical Services's property, plant, and equipment additions decreased by 42.6% year-over-year, from $75.2M to $43.2M.
Ask your AI about West Pharmaceutical Services's property, plant, and equipment additions.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude